The roles of microRNAs in the pathogenesis and drug resistance of chronic myelogenous leukemia (Review)
- Authors:
- Carla Di Stefano
- Giovanna Mirone
- Stefania Perna
- Gabriella Marfe
-
Affiliations: Department of Hematology, ‘Tor Vergata’ University, I-00133 Rome, Italy, Department of Medical Oncology B, Regina Elena National Cancer Institute, I-00144 Rome, Italy, Department of Scienze e Tecnologie Ambientali, Biologiche e Farmaceutiche, Seconda Università di Napoli, I-81100 Caserta, Italy - Published online on: November 26, 2015 https://doi.org/10.3892/or.2015.4456
- Pages: 614-624
This article is mentioned in:
Abstract
Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R and Kantarjian HM: The biology of chronic myeloid leukemia. N Engl J Med. 341:164–172. 1999. View Article : Google Scholar : PubMed/NCBI | |
Kantarjian HM, Dixon D, Keating MJ, Talpaz M, Walters RS, McCredie KB and Freireich EJ: Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer. 61:1441–1446. 1988. View Article : Google Scholar : PubMed/NCBI | |
Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z and Talpaz M: Chronic myelogenous leukemia: A concise update. Blood. 82:691–703. 1993.PubMed/NCBI | |
Rudkin CT, Hungerford DA and Nowell PC: DNA contents of chromosome Ph1 and chromosome 21 in human chronic granulocytic leukemia. Science. 144:1229–1231. 1964. View Article : Google Scholar : PubMed/NCBI | |
Druker BJ: Translation of the Philadelphia chromosome into therapy for CML. Blood. 112:4808–4817. 2008. View Article : Google Scholar : PubMed/NCBI | |
Holyoake DT: Recent advances in the molecular and cellular biology of chronic myeloid leukaemia: Lessons to be learned from the laboratory. Br J Haematol. 113:11–23. 2001. View Article : Google Scholar : PubMed/NCBI | |
Asimakopoulos FA, Shteper PJ, Krichevsky S, Fibach E, Polliack A, Rachmilewitz E, Ben-Neriah Y and Ben-Yehuda D: ABL1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia. Blood. 94:2452–2460. 1999.PubMed/NCBI | |
Mancini M, Veljkovic N, Leo E, Aluigi M, Borsi E, Galloni C, Iacobucci I, Barbieri E and Santucci MA: Cytoplasmatic compartmentalization by Bcr-Abl promotes TET2 loss-of-function in chronic myeloid leukemia. J Cell Biochem. 113:2765–2774. 2012. View Article : Google Scholar : PubMed/NCBI | |
Huang Q, Yang Y, Li X and Huang S: Transcription suppression of SARI (suppressor of AP-1, regulated by IFN) by BCR-ABL in human leukemia cells. Tumour Biol. 32:1191–1197. 2011. View Article : Google Scholar : PubMed/NCBI | |
Bixby D and Talpaz M: Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. HHematology Am Soc Hematol Educ Program. 1:461–476. 2009. View Article : Google Scholar | |
Mughal A, Aslam HM, Khan AM, Saleem S, Umah R and Saleem M: Bcr-Abl tyrosine kinase inhibitors - current status. Infect Agent Cancer. 8(23)2013. View Article : Google Scholar | |
Asaki T, Sugiyama Y, Hamamoto T, Higashioka M, Umehara M, Naito H and Niwa T: Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors. Bioorg Med Chem Lett. 16:1421–1425. 2006. View Article : Google Scholar | |
Eck MJ and Manley PW: The interplay of structural information and functional studies in kinase drug design: Insights from BCR-Abl. Curr Opin Cell Biol. 21:288–295. 2009. View Article : Google Scholar : PubMed/NCBI | |
An X, Tiwari AK, Sun Y, Ding P-R, Ashby CR Jr and Chen ZS: BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: A review. Leuk Res. 34:1255–1268. 2010. View Article : Google Scholar : PubMed/NCBI | |
Stein B and Smith BD: Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib. Clin Ther. 32:804–820. 2010. View Article : Google Scholar : PubMed/NCBI | |
Thomas J, Wang L, Clark RE and Pirmohamed M: Active transport of imatinib into and out of cells: Implications for drug resistance. Blood. 104:3739–3745. 2004. View Article : Google Scholar : PubMed/NCBI | |
Jabbour E, Cortes J and Kantarjian H: Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review. Core Evid. 4:207–213. 2009. View Article : Google Scholar | |
Manley PW, Cowan-Jacob SW and Mestan J: Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia. Biochim Biophys Acta. 1754:3–13. 2005. View Article : Google Scholar : PubMed/NCBI | |
Olivieri A and Manzione L: Dasatinib: A new step in molecular target therapy. Ann Oncol. 18(Suppl 6): vi42–vi46. 2007. View Article : Google Scholar : PubMed/NCBI | |
O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, et al: AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 16:401–412. 2009. View Article : Google Scholar : PubMed/NCBI | |
FDA Drug Safety Communication: FDA asks manufacturer of the leukemia drug Iclusig (ponatinib) to suspend marketing and sales. U.S. Food and Drug Administration. 2013, http://www.fda.gov/Drugs/DrugSafety/ucm373040.htm. Accessed Nov 26, 2013. | |
Lipshultz SE, Diamond MB, Franco VI, Aggarwal S, Leger K, Santos MV, Sallan SE and Chow EJ: Managing chemotherapy-related cardiotoxicity in survivors of childhood cancers. Paediatr Drugs. 16:373–389. 2014. View Article : Google Scholar : PubMed/NCBI | |
Kimura S, Naito H, Segawa H, Kuroda J, Yuasa T, Sato K, Yokota A, Kamitsuji Y, Kawata E, Ashihara E, et al: NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood. 106:3948–3954. 2005. View Article : Google Scholar : PubMed/NCBI | |
Horio T, Hamasaki T, Inoue T, Wakayama T, Itou S, Naito H, Asaki T, Hayase H and Niwa T: Structural factors contributing to the Abl/Lyn dual inhibitory activity of 3-substituted benzamide derivatives. Bioorg Med Chem Lett. 17:2712–2717. 2007. View Article : Google Scholar : PubMed/NCBI | |
Valent P: Standard treatment of Ph+ CML in 2010: How, when and where not to use what BCR/ABL1 kinase inhibitor? Eur J Clin Invest. 40:918–931. 2010. View Article : Google Scholar : PubMed/NCBI | |
Peláez N and Carthew RW: Biological robustness and the role of microRNAs: A network perspective. Curr Top Dev Biol. 99:237–255. 2012. View Article : Google Scholar : PubMed/NCBI | |
Nam JW, Rissland OS, Koppstein D, Abreu-Goodger C, Jan CH, Agarwal V, Yildirim MA, Rodriguez A and Bartel DP: Global analyses of the effect of different cellular contexts on microRNA targeting. Mol Cell. 53:1031–1043. 2014. View Article : Google Scholar : PubMed/NCBI | |
Di Leva G, Garofalo M and Croce CM: MicroRNAs in cancer. Annu Rev Pathol. 9:287–314. 2014. View Article : Google Scholar : | |
Lee R, Feinbaum R and Ambros V: The heterochronic gene lin-4 of C. elegans encodes small RNAs with antisense complementarity to lin-14. Cell. 75:843–854. 1993. View Article : Google Scholar : PubMed/NCBI | |
Kozomara A and Griffiths-Jones S: miRBase: Integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res. 39:D152–D157. 2011. View Article : Google Scholar : | |
Tsai LM and Yu D: MicroRNAs in common diseases and potential therapeutic applications. Clin Exp Pharmacol Physiol. 37:102–107. 2010. View Article : Google Scholar | |
Esquela-Kerscher A and Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006. View Article : Google Scholar : PubMed/NCBI | |
Masaki S, Ohtsuka R, Abe Y, Muta K and Umemura T: Expression patterns of microRNAs 155 and 451 during normal human erythropoiesis. Biochem Biophys Res Commun. 364:509–514. 2007. View Article : Google Scholar : PubMed/NCBI | |
Wang Y and Blelloch R: Cell cycle regulation by microRNAs in embryonic stem cells. Cancer Res. 69:4093–4096. 2009. View Article : Google Scholar : PubMed/NCBI | |
Subramanian S and Steer CJ: MicroRNAs as gatekeepers of apoptosis. J Cell Physiol. 223:289–298. 2010.PubMed/NCBI | |
Schwarz DS, Hutvágner G, Du T, Xu Z, Aronin N and Zamore PD: Asymmetry in the assembly of the RNAi enzyme complex. Cell. 115:199–208. 2003. View Article : Google Scholar : PubMed/NCBI | |
Berezikov E, Chung WJ, Willis J, Cuppen E and Lai EC: Mammalian mirtron genes. Mol Cell. 28:328–336. 2007. View Article : Google Scholar : PubMed/NCBI | |
Hinske LC, Galante PA, Kuo WP and Ohno-Machado L: A potential role for intragenic miRNAs on their hosts' interactome. BMC Genomics. 11:533–541. 2010. View Article : Google Scholar : PubMed/NCBI | |
Bagga S, Bracht J, Hunter S, Massirer K, Holtz J, Eachus R and Pasquinelli AE: Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation. Cell. 122:553–563. 2005. View Article : Google Scholar : PubMed/NCBI | |
Ørom UA, Nielsen FC and Lund AH: MicroRNA-10a binds the 5′UTR of ribosomal protein mRNAs and enhances their translation. Mol Cell. 30:460–471. 2008. View Article : Google Scholar | |
Vasudevan S, Tong Y and Steitz JA: Switching from repression to activation: microRNAs can up-regulate translation. Science. 318:1931–1934. 2007. View Article : Google Scholar : PubMed/NCBI | |
Pillai RS, Bhattacharyya SN, Artus CG, Zoller T, Cougot N, Basyuk E, Bertrand E and Filipowicz W: Inhibition of translational initiation by let-7 MicroRNA in human cells. Science. 309:1573–1576. 2005. View Article : Google Scholar : PubMed/NCBI | |
Hendrickson DG, Hogan DJ, McCullough HL, Myers JW, Herschlag D, Ferrell JE and Brown PO: Concordant regulation of translation and mRNA abundance for hundreds of targets of a human microRNA. PLoS Biol. 7:e10002382009. View Article : Google Scholar : PubMed/NCBI | |
Choe J, Cho H, Lee HC and Kim YK: microRNA/Argonaute 2 regulates nonsense-mediated messenger RNA decay. EMBO Rep. 11:380–386. 2010. View Article : Google Scholar : PubMed/NCBI | |
Cuccato G, Polynikis A, Siciliano V, Graziano M, di Bernardo M and di Bernardo D: Modeling RNA interference in mammalian cells. BMC Syst Biol. 5:19–24. 2011. View Article : Google Scholar : PubMed/NCBI | |
Hemida MG, Ye X, Thair S and Yang D: Exploiting the therapeutic potential of microRNAs in viral diseases: Expectations and limitations. Mol Diagn Ther. 14:271–282. 2010. View Article : Google Scholar : PubMed/NCBI | |
Bader AG, Brown D and Winkler M: The promise of microRNA replacement therapy. Cancer Res. 70:7027–7030. 2010. View Article : Google Scholar : PubMed/NCBI | |
Chen CZ: MicroRNAs as oncogenes and tumor suppressors. N Engl J Med. 353:1768–1771. 2005. View Article : Google Scholar : PubMed/NCBI | |
Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al: MicroRNA expression profiles classify human cancers. Nature. 435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI | |
Zhang H, Luo XQ, Zhang P, Huang LB, Zheng YS, Wu J, Zhou H, Qu LH, Xu L and Chen YQ: MicroRNA patterns associated with clinical prognostic parameters and CNS relapse prediction in pediatric acute leukemia. PLoS One. 4:e78262009. View Article : Google Scholar : PubMed/NCBI | |
Labbaye C and Testa U: The emerging role of MIR-146A in the control of hematopoiesis, immune function and cancer. J Hematol Oncol. 5(13)2012. View Article : Google Scholar : PubMed/NCBI | |
Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, et al: A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med. 353:1793–1801. 2005. View Article : Google Scholar : PubMed/NCBI | |
Garzon R, Volinia S, Liu CG, Fernandez-Cymering C, Palumbo T, Pichiorri F, Fabbri M, Coombes K, Alder H, Nakamura T, et al: MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood. 111:3183–3189. 2008. View Article : Google Scholar : PubMed/NCBI | |
Gimenes-Teixeira HL, Lucena-Araujo AR, Dos Santos GA, Zanette DL, Scheucher PS, Oliveira LC, Dalmazzo LF, Silva-Júnior WA, Falcão RP and Rego EM: Increased expression of miR-221 is associated with shorter overall survival in T-cell acute lymphoid leukemia. Exp Hematol Oncol. 2(10)2013. View Article : Google Scholar : PubMed/NCBI | |
Jongen-Lavrencic M, Sun SM, Dijkstra MK, Valk PJ and Löwenberg B: MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood. 111:5078–5085. 2008. View Article : Google Scholar : PubMed/NCBI | |
Fernando TR, Rodriguez-Malave NI and Rao DS: MicroRNAs in B cell development and malignancy. J Hematol Oncol. 5(7)2012. View Article : Google Scholar : PubMed/NCBI | |
Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, et al: Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 99:15524–15529. 2002. View Article : Google Scholar | |
Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, et al: miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA. 102:13944–13949. 2005. View Article : Google Scholar : PubMed/NCBI | |
Xu L, Xu Y, Jing Z, Wang X, Zha X, Zeng C, Chen S, Yang L, Luo G, Li B, et al: Altered expression pattern of miR-29a, miR-29b and the target genes in myeloid leukemia. Exp Hematol Oncol. 3(17)2014. View Article : Google Scholar : PubMed/NCBI | |
Seca H, Lima RT, Lopes-Rodrigues V, Guimaraes JE, Almeida GM and Vasconcelos MH: Targeting miR-21 induces autophagy and chemosensitivity of leukemia cells. Curr Drug Targets. 14:1135–1143. 2013. View Article : Google Scholar : PubMed/NCBI | |
Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamur S, Shimizu M, Rattan S, Bullrich F, Negrini M, et al: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA. 101:2999–3004. 2004. View Article : Google Scholar : PubMed/NCBI | |
Agirre X, Jiménez-Velasco A, San José-Enériz E, Garate L, Bandrés E, Cordeu L, Aparicio O, Saez B, Navarro G, Vilas-Zornoza A, et al: Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth. Mol Cancer Res. 6:1830–1840. 2008. View Article : Google Scholar : PubMed/NCBI | |
Wang LS, Li L, Li L, Chu S, Shiang KD, Li M, Sun HY, Xu J, Xiao FJ, Sun G, et al: MicroRNA-486 regulates normal eryth-ropoiesis and enhances growth and modulates drug response in CML progenitors. Blood. 125:1302–1313. 2015. View Article : Google Scholar : | |
Babashah S, Sadeghizadeh M, Hajifathali A, Tavirani MR, Zomorod MS, Ghadiani M and Soleimani M: Targeting of the signal transducer Smo links microRNA-326 to the oncogenic Hedgehog pathway in CD34+ CML stem/progenitor cells. Int J Cancer. 133:579–589. 2013. View Article : Google Scholar : PubMed/NCBI | |
Venturini L, Battmer K, Castoldi M, Schultheis B, Hochhaus A, Muckenthaler MU, Ganser A, Eder M and Scherr M: Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. Blood. 109:4399–4405. 2007. View Article : Google Scholar : PubMed/NCBI | |
Eiring AM, Harb JG, Neviani P, Garton C, Oaks JJ, Spizzo R, Liu S, Schwind S, Santhanam R, Hickey CJ, et al: miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell. 140:652–665. 2010. View Article : Google Scholar : PubMed/NCBI | |
Chang JS, Santhanam R, Trotta R, Neviani P, Eiring AM, Briercheck E, Ronchetti M, Roy DC, Calabretta B, Caligiuri MA, et al: High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP E2 dependent suppression of C/EBPalpha-driven myeloid differentiation. Blood. 110:994–1003. 2007. View Article : Google Scholar : PubMed/NCBI | |
Perrotti D, Cesi V, Trotta R, Guerzoni C, Santilli G, Campbell K, Iervolino A, Condorelli F, Gambacorti-Passerini C, Caligiuri MA, et al: BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2. Nat Genet. 30:48–58. 2002. View Article : Google Scholar | |
Machová Poláková K, Lopotová T, Klamová H, Burda P, Trněný M, Stopka T and Moravcová J: Expression patterns of microRNAs associated with CML phases and their disease related targets. Mol Cancer. 10(41)2011. View Article : Google Scholar : PubMed/NCBI | |
Flamant S, Ritchie W, Guilhot J, Holst J, Bonnet ML, Chomel JC, Guilhot F, Turhan AG and Rasko JE: Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia. Haematologica. 95:1325–1333. 2010. View Article : Google Scholar : PubMed/NCBI | |
Rokah OH, Granot G, Ovcharenko A, Modai S, Pasmanik-Chor M, Toren A, Shomron N and Shpilberg O: Downregulation of miR-31, miR-155, and miR-564 in chronic myeloid leukemia cells. PLoS One. 7:e355012012. View Article : Google Scholar : PubMed/NCBI | |
Suresh S, McCallum L, Lu W, Lazar N, Perbal B and Irvine AE: MicroRNAs 130a/b are regulated by BCR-ABL and down-regulate expression of CCN3 in CML. J Cell Commun Signal. 5:183–191. 2011. View Article : Google Scholar : PubMed/NCBI | |
Hershkovitz-Rokah O, Modai S, Pasmanik-Chor M, Toren A, Shomron N, Raanani P, Shpilberg O and Granot G: Restoration of miR-424 suppresses BCR-ABL activity and sensitizes CML cells to imatinib treatment. Cancer Lett. 360:245–256. 2015. View Article : Google Scholar : PubMed/NCBI | |
Fallah P, Amirizadeh N, Poopak B, Toogeh G, Arefian E, Kohram F, Hosseini Rad SM, Kohram M, Teimori Naghadeh H and Soleimani M: Expression pattern of key microRNAs in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Int J Lab Hematol. 37:560–568. 2015. View Article : Google Scholar : PubMed/NCBI | |
Bhamidipati PK, Kantarjian H, Cortes J, Cornelison AM and Jabbour E: Management of imatinib-resistant patients with chronic myeloid leukemia. Ther Adv Hematol. 4:103–117. 2013. View Article : Google Scholar : PubMed/NCBI | |
Taganov KD, Boldin MP, Chang KJ and Baltimore D: NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA. 103:12481–12486. 2006. View Article : Google Scholar : PubMed/NCBI | |
Duncan EA, Goetz CA, Stein SJ, Mayo KJ, Skaggs BJ, Ziegelbauer K, Sawyers CL and Baldwin AS: IkappaB kinase beta inhibition induces cell death in imatinib-resistant and T315I Dasatinib-resistant BCR-ABL+ cells. Mol Cancer Ther. 7:391–397. 2008. View Article : Google Scholar : PubMed/NCBI | |
Xu C, Fu H, Gao L, Wang L, Wang W, Li J, Li Y, Dou L, Gao X, Luo X, et al: BCR-ABL/GATA1/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia. Oncogene. 33:44–54. 2014. View Article : Google Scholar | |
Turrini E, Haenisch S, Laechelt S, Diewock T, Bruhn O and Cascorbi I: MicroRNA profiling in K-562 cells under imatinib treatment: Influence of miR-212 and miR-328 on ABCG2 expression. Pharmacogenet Genomics. 22:198–205. 2012. View Article : Google Scholar : PubMed/NCBI | |
Yu Y, Yang L, Zhao M, Zhu S, Kang R, Vernon P, Tang D and Cao L: Targeting microRNA-30a-mediated autophagy enhances imatinib activity against human chronic myeloid leukemia cells. Leukemia. 26:1752–1760. 2012. View Article : Google Scholar : PubMed/NCBI | |
Shibuta T, Honda E, Shiotsu H, Tanaka Y, Vellasamy S, Shiratsuchi M and Umemura T: imatinib induces demethylation of miR-203 gene: An epigenetic mechanism of anti-tumor effect of imatinib. Leuk Res. 37:1278–1286. 2013. View Article : Google Scholar : PubMed/NCBI | |
San José-Enériz E, Román-Gómez J, Jiménez-Velasco A, Garate L, Martin V, Cordeu L, Vilas-Zornoza A, Rodríguez-Otero P, Calasanz MJ, Prósper F, et al: MicroRNA expression profiling in imatinib-resistant chronic myeloid leukemia patients without clinically significant ABL1-mutations. Mol Cancer. 8(69)2009. View Article : Google Scholar : PubMed/NCBI | |
Lopotová T, Záčková M, Klamová H and Moravcová J: MicroRNA-451 in chronic myeloid leukemia: miR-451-BCR-ABL regulatory loop? Leuk Res. 35:974–977. 2011. View Article : Google Scholar : PubMed/NCBI | |
Scholl V, Hassan R and Zalcberg IR: miRNA-451: A putative predictor marker of imatinib therapy response in chronic myeloid leukemia. Leuk Res. 36:119–121. 2012. View Article : Google Scholar | |
Zimmerman EI, Dollins CM, Crawford M, Grant S, Nana-Sinkam SP, Richards KL, Hammond SM and Graves LM: Lyn kinase-dependent regulation of miR181 and myeloid cell leukemia-1 expression: Implications for drug resistance in myelogenous leukemia. Mol Pharmacol. 78:811–817. 2010. View Article : Google Scholar : PubMed/NCBI | |
Liu L, Wang S, Chen R, Wu Y, Zhang B, Huang S, Zhang J, Xiao F, Wang M and Liang Y: Myc induced miR-144/451 contributes to the acquired imatinib resistance in chronic myelogenous leukemia cell K562. Biochem Biophys Res Commun. 425:368–373. 2012. View Article : Google Scholar : PubMed/NCBI | |
You RI, Ho CL, Hung HM and Chao TS: Identification of nilotinib-altered microRNA expression patterns in imatinib-resistant chronic myeloid leukemia cells. Biomark Genomic Med. 5:71–73. 2013. View Article : Google Scholar | |
Firatligil B, Biray Avci C and Baran Y: miR-17 in imatinib resistance and response to tyrosine kinase inhibitors in chronic myeloid leukemia cells. J BUON. 18:437–441. 2013.PubMed/NCBI | |
Mosakhani N, Mustjoki S and Knuutila S: Down-regulation of miR-181c in imatinib-resistant chronic myeloid leukemia. Mol Cytogenet. 6(27)2013. View Article : Google Scholar : PubMed/NCBI | |
Ohyashiki JH, Ohtsuki K, Mizoguchi I, Yoshimoto T, Katagiri S, Umezu T and Ohyashiki K: Downregulated microRNA-148b in circulating PBMCs in chronic myeloid leukemia patients with undetectable minimal residual disease: A possible biomarker to discontinue imatinib safely. Drug Des Devel Ther. 8:1151–1159. 2014. View Article : Google Scholar : PubMed/NCBI | |
Lin H, Rothe K, Ruschmann J, Petriv O, O'Neill K, Knapp D, Brinkman RR, Birol I, Forrest DL, Hansen C, et al: Identification of new microRNA biomarkers and candidate target genes in primitive CML cells using global comparative RNA analyses. 3133 Poster AHA; 2014 | |
Joshi D, Chandrakala S, Korgaonkar S, Ghosh K and Vundinti BR: Down-regulation of miR-199b associated with imatinib drug resistance in 9q34.1 deleted BCR/ABL positive CML patients. Gene. 542:109–112. 2014. View Article : Google Scholar : PubMed/NCBI | |
Nishioka C, Ikezoe T, Yang J, Nobumoto A, Tsuda M and Yokoyama A: Downregulation of miR-217 correlates with resistance of Ph+ leukemia cells to ABL tyrosine kinase inhibitors. Cancer Sci. 105:297–307. 2014. View Article : Google Scholar |